Autologous Stem Cells Transplantation for No-Option Angiitis-Induced Critical Limb Ischemia: Recurrence and New Lesion

Hao Liu, Yuan Fang, Tianyue Pan, Gang Fang, Yifan Liu, Xiaolang Jiang, Bin Chen, Shiyang Gu, Zheng Wei, Peng Liu, Weiguo Fu, Jue Yang, Zhihui Dong
Autologous Stem Cells Transplantation for No-Option Angiitis-Induced Critical Limb Ischemia: Recurrence and New Lesion

Hao Liu1,2†, Yuan Fang1,2, Tianyue Pan1,2, Gang Fang1,2, Yifan Liu1,2, Xiaolang Jiang1,2, Bin Chen1,2, Shiyang Gu3, Zheng Wei3, Peng Liu3, Weiguo Fu1,2, Jue Yang1,2, Zhihui Dong1,2,*

1Department of Vascular Surgery of Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China
2National Clinical Research Center for Interventional Medicine, Shanghai, People's Republic of China
3Department of Hematology of Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China

*Corresponding author: Zhihui Dong, MD, Department of Vascular Surgery, Zhongshan Hospital affiliated to Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China. Tel: +86 13564249168. Email: dzh92680126.com; or, Jue Yang, MD, Department of Vascular Surgery, Zhongshan Hospital Affiliated to Fudan University, 180 Fenglin Road, Shanghai 200032, People's Republic of China. Tel: +86 17621923342. Email: yang.jue@zs-hospital.sh.cn
†These authors contributed equally to this work.

Abstract

Although satisfying outcomes have been demonstrated in terms of autologous stem cell transplantation in the treatment of angiitis-induced critical limb ischemia (AICLI), few studies have systematically reported the recurrence conditions. In the current study, we aimed to investigate recurrence conditions of a relatively large AICLI cohort in our center during a long-term follow-up period. From May 2009 to August 2020, 181 patients with AICLI received peripheral blood mononuclear cells (PBMNCs) or purified CD34+ cells (PCCs) transplantation. The main outcomes included recurrence and new lesions. Patient demographic data, ischemic limb characteristics, interventional characteristics, etc., were identified and analyzed. A logistic multivariable regression was performed to identify the independent risk factors for recurrence by a stepwise selection of variables. One hundred forty-eight patients were enrolled in this study. The mean follow-up period was 62.3 ± 37.4 months (range 12-144 months). The 5- and 10-year recurrence-free rates were 88.5% (95% confidence interval [CI] 3.1%-82.6%) and 71.7% (95% CI 7.6%-58.2%), respectively. The 5- and 10-year new lesion-free rates were 93.2% (95% CI 2.2%-89.0%) and 91.7% (95% CI 2.7%-86.6%), respectively. The finding of multiple limbs involved (OR 1.322 95% CI 1.123-1.549, P = .036) and ischemia relief period ≥5 months (OR 3.367 95% CI 1.112-10.192, P = .032) were demonstrated to be independent risk factors for recurrence in patients with AICLI who underwent cell transplantation. For patients with AICLI who responded to cell transplantation, the durability of this therapy was satisfactory, with 5- and 10-year recurrence-free rates of 88.5% and 71.7%, respectively. Multiple limbs involved at admission and ischemia relief period ≥5 months were demonstrated to be independent risk factors for recurrence after transplantation.

Key words: cells transplantation; cell therapy; critical limb ischemia; recurrence.

Graphic Abstract

AICLI patients with multiple ischemic limbs seem to be more likely to develop recurrence after cell transplantation. AICLI, angiitis-induced critical limb ischemia.
Lessons Learned
• Recurrence of angiitis-induced critical limb ischemia (AICLI) was observed in 18 patients during the follow-up (62.3 ± 37.4 months) and the 5- and 10-year recurrence-free rates were 88.5% and 71.7%, respectively.
• This suggests a satisfactory durability of cell therapy in treating AICLI.
• Patients with multiple limbs involved at admission and/or a ≥5 months post-transplantation ischemia relief period seemed more likely to develop recurrence after transplantation.

Significance Statement
Although satisfying efficacy and safety outcomes have been demonstrated in terms of autologous stem cell transplantation in the treatment of angiitis-induced critical limb ischemia in many studies, few studies reported the conditions of patients’ recurrence. The current study reported the 5- and 10-year recurrence-free rates of 88.5% and 71.7%, respectively. Multiple ischemic limbs at admission and ischemia relief period ≥5 months was demonstrated to be independent risk factors for recurrence after transplantation.

Introduction
Critical limb ischemia (CLI) is a classic vascular disease caused by various etiologies and is associated with a high major amputation rate and mortality.1 After surgical and endovascular reconstruction, most patients obtained relief, while 15%-20% of patients with CLI did not.1 These patients are also called patients with no-option critical limb ischemia (NO-CLI), and NO-CLI is defined as a CLI that is unsuitable for either surgical or endovascular treatment owing to a high postoperative reocclusion rate and poor anatomical conditions.2 Currently, satisfying efficacy and safety outcomes have been demonstrated in terms of autologous stem cell transplantation in the treatment of NO-CLI in many studies.3-6 Due to the common propensity for affecting and destroying the anatomic run-off necessary for either endovascular or surgical reconstruction, angiitis-induced critical limb ischemia (AICLI), which is defined as CLI caused by thromboangiitis obliterans (TAO) or other arteritis-related autoimmune diseases (such as systemic lupus erythematosus (SLE), psoriasis, Crohn’s disease, etc.), is found to constitute a large proportion of patients with NO-CLI. Our center launched a clinical study of cell transplantation (including peripheral blood mononuclear cells [PBMNCs] and CD34+ cells [PCCs]) in treating AICLI since 2009, and more than 190 patients have so far been treated to the present day.

Although the limb salvage rate of the therapy is promising, a certain number of patients with AICLI still developed recurrent CLI with an extension of the follow-up,3,6 and only a few studies have reported the recurrence of patients with NO-CLI who received cell transplantation systematically. This might have resulted from the limited numbers of patients in the single studies and the relatively short follow-up. Recurrence, which is defined as transplanted limbs returning to the CLI condition after prior ischemia relief, partly reflects the durability of the cell therapy.

In the current study, we aimed to investigate the recurrence condition of a relatively large AICLI cohort in our center during a long-term follow-up period.

Materials and Methods
The protocol was approved by the Ethics Committee of Zhongshan Hospital affiliated with Fudan University (approval number: No. 2009-016) and was conducted according to the World Medical Association’s Declaration of Helsinki. All participants provided written informed consent before enrollment.

Patients
From May 2009 to August 2020, 181 patients with AICLI received PBMNCs or PCCs transplantation. The inclusion and exclusion criteria for cell transplantation are detailed elsewhere.7 Briefly, patients aged between 18 and 80 years with AICLI (Rutherford class 4-5), which was confirmed by clinical manifestations and computed tomographic angiography (CTA), magnetic resonance angiography, or digital subtraction angiography, were included. The exclusion criteria were (1) serious health events (including but not limited to myocardial infarction, cerebral apoplexy, pulmonary embolism, and severe hepatic and renal dysfunction) that was diagnosed within the last 3 months, (2) a suspicion or a diagnosis of a malignancy at baseline, or (3) a life expectancy of no more than 6 months. In the current study, we also excluded patients who (1) did not achieve CLI relief within 12 months after transplantation (defined as nonresponders to cell therapy), (2) did not complete the 12-month follow-up (lost or died of non-AICLI-related reasons without recurrence/a new lesion) and (3) underwent a second cell transplantation.

Procedures for Cell Transplantation
The procedures were also detailed elsewhere.7 Subcutaneous injections of rhG-CSF (Neupogen; Amgen, Thousand Oaks, CA, USA) (5-10 μg/kg per day for 4 days) were given to mobilize the bone marrow cells, and enoxaparin (4000 IU/day) was given to prevent hypercoagulable states. On the fifth day, a suspension of PBMNCs was collected via leukapheresis (COM. TEC; Fresenius Hemocare GmbH, Bad Homburg, Germany). Then, after washing 3 times and resuspending the apheresis products in an ethylenediaminetetraacetic acid-phosphate-buffered saline solution (200 mL) that contained 0.5% human albumin, the PBMNCs cell product was obtained. The PCCs were obtained from the PBMNCs by using a magnetic cell sorting system (Miltenyi-Biotec GmbH, Bergisch-Gladbach, Germany). The total cell count of CD34+ cells was determined by leukocyte counting and flow cytometry. With the patients under general anesthesia, the cell products were transplanted into the ischemic limbs via equidistant intramuscular injections (0.5 mL/site).
Data Collection
During hospitalization, the patients’ demographic characteristics, characteristics of the autoimplants, critical results of blood examinations, etc., were recorded and analyzed. The baseline features of the patients, such as the numbers of involved limbs, the Rutherford scale, the transcutaneous pressure of oxygen (TcPO2) of the dorsum, the ankle-brachial index (ABI), and the occlusion level of the arteries, were also recorded.

Outcomes and Follow-up
The main outcomes included recurrence and the development of new lesions. Recurrence was defined as transplanted limbs returning to the CLI condition after prior ischemia relief, and a new lesion was defined as untransplanted nonischemic limbs that became CLI during the follow-up. The timepoints of recurrence and the development of new lesions after transplantation were also recorded. Patients were required to return for regular clinical visits at 1, 2, 3, 6, 9, and 12 months and then annually after transplantation. The relief of rest pain, healing of ulcers or gangrene, smoking cessation compliance, and medication compliance were assessed and recorded during the clinical visits. Rest pain was evaluated by Wong-Baker Faces Pain Rating Scale (WBFPS) (a score of 0 represents no pain and a score of 10 represents the greatest pain) and rest pain relief was defined as WBFPS ≤4. Patients’ ulcers or gangrene was recorded via taking pictures and compared with prior records. Conditions in terms of smoking cessation and medication compliance were asked at clinical visit or via telephone.

Statistical Analysis
The quantitative data, which were compared using Student’s t-test, are shown as the mean ± SD or as the median with the interquartile range (IQR), depending on their distribution. Categorical variables, presented as frequencies and percentages, were compared using the χ2 test or Fisher’s exact test. Logistic multivariable regression was performed to identify the independent risk factors for recurrence by a stepwise selection of variables. Factors with a P-value <.10 in the univariate analyses were introduced into the multivariate model. The recurrence-free and new lesion-free rates were analyzed by a Kaplan-Meier analysis. All statistical tests were performed using a 2-sided α of 0.05. All tests were performed using PASW software, version 19 (IBM Corporation, Armonk, NY, USA), or R, version 4.0.5.

Results
Baseline Characteristics
Between May 2009 and August 2020, 181 patients with AICLI who underwent cell transplantation for AICLI in our center were identified. After excluding the nonresponders and patients who did not complete the 12-month follow-up, 148 patients were finally enrolled in this study (Fig. 1). The percent of patients who were male was 98.6% (146/148), and the mean age of the patients was 42.0 ± 10.2 years (range 20-68 years). The patients were characterized by low frequencies of cardio-cerebrovascular risk factors except for high frequencies of smoking history (85.1%, 126/148). All patients were admitted with a Rutherford class of 4 (19 patients [12.8%]) or 5 (129 patients [87.2%]), and perioperative infections of ulcers/gangrene were observed in 19 patients (12.8%). Except for 8 patients with nonTAO-related angiitis, the remaining 140 patients (94.6%) were all diagnosed with TAO. One hundred thirty-six patients were admitted with single-limb AICLI, and the remaining 12 patients had 2 or more limbs involved. Sixty-three patients underwent prior interventions, including bypass, endarterectomy, stent grafting balloon angioplasty, thrombolysis and thrombectomy. More details of the baseline characteristics are shown in Table 1.

Interventional Characteristics
The mean duration for autoimplant harvest was 95.9 ± 32.5 minutes (range 50-140 minutes), and the mean duration for cell implantation was 37.4 ± 12.0 minutes (range 20-60 min). There were 69 (46.6%) patients who underwent PCCs...
transplantation, and the remaining 79 (53.4%) patients received PBMCs transplantation. Concurrent debridement during transplantation was performed in 13 patients owing to the severe infection of patients’ ulcers/gangrene. The median number of CD34+ cells transplanted was $41.0 \times 10^6$ (interquartile range [IQR] $25.2 \times 10^6$-$71.9 \times 10^6$), and the median number of CD34+ cells transplanted per kg was $6.1 \times 10^5$/kg (IQR $3.6 \times 10^5$-$11.7 \times 10^5$/kg) (Table 2).

Follow-up
The mean follow-up period was $62.3 \pm 37.4$ months (range 12-144 months). All patients achieved AICLI relief.
with a mean lesion-free period of 3.6 ± 2.6 months (range 1-12 months). Two patients died during the follow-up: one patient died of heart failure at 27 months, and one died of stroke at 25 months. Strict smoking cessation was achieved in 39 (31.0%, 39/126) patients, and 48 (32.4%) patients were compliant with their drug therapy. Recurrence of AICLI was observed in 18 out of 148 patients (Table 3). There were 17 TAO-induced AICLI male patients, but there was only 1 SLE-induced female patient with AICLI. The mean period between the first transplantation and recurrence was 46.0 ± 30.5 months (range 8-106 months). Sixteen patients presented with recurrent ulcers/gangrene (Rutherford class 3), and 2 presented with resting pain (Rutherford class 4). One patient with recurrence was also admitted with a new lesion. Among all 18 patients, 4 patients had ischemia relief after conservative treatment; among the remaining 14 patients, 12 received second transplantations, 1 refused cell transplantation, and 1 patient had an amputation due to rapid progression of ischemia and severe gangrenous infection. Regarding the 12 patients with a second transplantation, ischemia relief was achieved in most of the patients (83.3%, 10/12), and the remaining 2 patients who did not have relief underwent amputation at 4 months and died of stroke at 25 months. The 5- and 10-year recurrence-free rates were 88.5% (95% confidence interval [CI] 3.1%-82.6%) and 71.7% (95% CI 7.6%-58.2%), respectively (Fig. 2A). New lesions were observed in 10 patients during the follow-up and 1 patient had concurrent recurrence (Table 3). All patients were male TAO patients with a mean new lesion period of 23.0 ± 15.9 months (range 7-61 months). No ischemia relief was observed only in patients with conservative treatment only, and 1 patient underwent an amputation. Seven patients received second cell transplantsations, and 6 of them achieved ischemia relief. A significantly higher proportion of patients with prior PCCs transplantation was observed in the group of patients with new lesions (8/69 vs 2/79, P = .028). The 5- and 10-year new lesion-free rates were 93.2% (95% CI 2.2%-89.0%) and 91.7% (95% CI 2.7%-86.6%), respectively (Fig. 2B).

### Risk Factors for Recurrence

Compared with the patients without recurrence, the patients with recurrence were characterized by higher proportions of patients with perioperative ulcers/gangrenous infection (6/18 vs 13/130, P = .009) and with multiple limbs involved by AICLI (4/18 vs 8/130, P = .041). No significant differences were observed between the 2 groups in terms of the other demographic characteristics, etiologies, risk factors for cardiovascular disease, or treatment histories (Table 1). Regarding the transplantation procedure, the patients with recurrence seemed more likely to undergo concurrent debridement (5/18 vs. 8/130, P = .011), while there was no significant difference in terms of the number of autotransplants that were given (Table 2). After transplantation, patients with recurrence were characterized by a longer ischemia relief period (5.5 ± 3.1 months vs 3.6 ± 2.3 months, P = .002), and there was a higher proportion of patients who had a ≥5-month ischemia relief period (10/18 vs 31/130, P = .015) in the patients with recurrence group. There were 136 patients (14 patients with recurrence and 126 not) with smoking history and 39 patients who achieved smoking cessation (1 patient with recurrence and 38 not). In addition, 87 patients continued smoking after transplantation (13 patients with recurrence and 74 not).

According to the results of the univariate logistic regression, several variables were screened out: perioperative ulcers/gangrenous infection (OR [odds ratio] 4.500, 95% CI [confidence interval] 1.162-16.335, P = .041), multiple limbs involved by AICLI (OR 4.357, 95% CI 1.162-16.335, P = .041), concurrent debridement during cell transplantation (OR 5.865, 95% CI 1.672-20.578, P = .011), an ischemia relief period ≥5 months (OR 3.254, 95% CI 1.261-8.397, P = .015) and the post-transplantation smoking condition (smoking cessation [OR 0.791, 95% CI 0.230-2.714, P = .709], not quit smoking

### Table 2. Comparison of intervention and postoperative characteristics between 2 groups of patients.

| Cell product | Total (n = 148) | Patients with recurrence (n = 18) | Patients without recurrence (n = 130) | P-value |
|--------------|----------------|----------------------------------|--------------------------------------|---------|
| Harvest time, minute, mean ± SD | 95.9 ± 32.5 | 100.3 ± 31.6 | 95.6 ± 32.2 | .562 |
| PBMCNs, n (%) | 79 (53.4) | 8 (5.4) | 71 (48.0) | .418 |
| PCCs, n (%) | 69 (46.6) | 10 (6.8) | 59 (39.8) | .418 |
| CD34+ cells, (10^6/kg) (median, IQR) | 41.0 (25.2-79.1) | 43.6 (28.3-84.9) | 41.0 (25.2-79.0) | .146 |
| CD34+ cells/kg, (10^6) (median, IQR) | 6.1 (3.6-11.7) | 6.4 (4.6-13.2) | 5.8 (3.6-11.0) | .254 |
| Cell viability, % (median, IQR) | 98.6 (97.8-99.4) | 98.8 (98.0-99.2) | 98.6 (97.9-99.4) | .798 |
| Transplantation time, minute, mean ± SD | 37.4 ± 12.0 | 37.3 ± 11.3 | 37.5 ± 13.2 | .951 |
| Concurrent debridement | 13 (8.8) | 5 (3.4) | 8 (5.4) | .011 |
| Ischemia relief period, months, mean ± SD | 3.6 ± 2.6 | 5.5 ± 3.1 | 3.6 ± 2.3 | .002 |
| Ischemia relief period ≥5 months, n (%) | 41 (27.7) | 10 (6.8) | 31 (20.9) | .015 |
| Persistent drug therapy | 48 (32.4) | 4 (2.7) | 44 (29.7) | .323 |
| Post-transplantation smoking condition | | | | |
| Smoking cessation | 39 (26.4) | 1 (0.7) | 38 (25.7) | |
| Not quitting smoking | 87 (58.8) | 13 (8.8) | 74 (50.0) | .094 |
| Without smoking history | 22 (14.8) | 4 (2.7) | 18 (12.1) | |

The data presented are the numbers (%) and the means ± standard deviations or medians and the interquartile ranges.

1. Ischemia relief period was defined as the time period between the first transplantation and postoperative critical limb ischemia relief (Rutherford class <4).

Abbreviations: PBMCNs, peripheral blood mononuclear cells; PCCs, purified CD34+ cells; IQR, interquartile range; CRP, C-reactive protein; GHb, glycosylated hemoglobin; GFR, glomerular filtration rate; ESR, erythrocyte sedimentation rate.
Stem Cells Translational Medicine, 2022, Vol. XX, No. XX

After the logistic multivariable regression analyses, multiple limbs involved (OR 1.322 95% CI 1.123-1.549, \( P = .036 \)) and ischemia relief period \( \geq 5 \) months (OR 3.367 95% CI 1.112-10.192, \( P = .032 \)) were demonstrated to be independent risk factors for recurrence.

### Table 3. Characteristics of patients with recurrence and/or new lesion.

| Patient number | Sex | Age | Etiology | Autoimplant type | R or N | Period/months | Rutherford class | Measures | Outcomes |
|----------------|-----|-----|----------|------------------|-------|---------------|------------------|----------|----------|
| 1              | M   | 34  | TAO      | PCCs             | R     | 8             | 5                | 2nd transplantation | Ischemia relief |
| 2              | M   | 72  | TAO      | PBMCNs           | R     | 8             | 4                | 2nd transplantation | Unrelieved |
| 3              | M   | 32  | TAO      | PBMCNs           | R     | 19            | 5                | 2nd transplantation | Ischemia relief |
| 4              | M   | 50  | TAO      | PBMCNs           | R     | 23            | 5                | Conservative treatment | Unrelieved |
| 5              | M   | 47  | TAO      | PCCs             | R     | 25            | 4                | Conservative treatment | Ischemia relief |
| 6              | M   | 42  | TAO      | PBMCNs           | R     | 26            | 5                | 2nd transplantation | Ischemia relief |
| 7              | M   | 30  | TAO      | PCCs             | R     | 27            | 5                | 2nd transplantation | Unrelieved+amputation |
| 8              | M   | 37  | TAO      | PBMCNs           | R     | 29            | 5                | Amputation\(^{a}\) | - |
| 9              | M   | 59  | TAO      | PBMCNs           | R     | 31            | 5                | Conservative treatment | Ischemia relief |
| 10             | M   | 52  | TAO      | PCCs             | R     | 40            | 5                | Conservative treatment | Ischemia relief |
| 11             | M   | 52  | TAO      | PBMCNs           | R     | 44            | 5                | 2nd transplantation | Ischemia relief |
| 12             | M   | 50  | TAO      | PCCs             | R     | 58            | 5                | 2nd transplantation | Ischemia relief |
| 13             | M   | 51  | TAO      | PBMCNs           | R     | 69            | 5                | 2nd transplantation | Ischemia relief |
| 14             | M   | 41  | TAO      | PCCs             | R     | 96            | 5                | 2nd transplantation | Ischemia relief |
| 15             | M   | 33  | TAO      | PCCs             | R     | 101           | 5                | 2nd transplantation | Ischemia relief |
| 16             | M   | 47  | TAO      | PCCs             | R     | 106           | 5                | 2nd transplantation | Ischemia relief |
| 17             | F   | 45  | SLE      | PCCs             | R     | 77            | 5                | Conservative treatment | Ischemia relief |
| 18             | M   | 46  | TAO      | PCCs             | R+N   | 22            | 5                | 2nd transplantation | Ischemia relief |
| 19             | M   | 35  | TAO      | PCCs             | N     | 61            | 5                | 2nd transplantation | Ischemia relief |
| 20             | M   | 43  | TAO      | PCCs             | N     | 14            | 5                | 2nd transplantation | Ischemia relief |
| 21             | M   | 34  | TAO      | PCCs             | N     | 20            | 5                | 2nd transplantation | Ischemia relief |
| 22             | M   | 36  | TAO      | PCCs             | N     | 27            | 5                | 2nd transplantation | Ischemia relief |
| 23             | M   | 50  | TAO      | PCCs             | N     | 7             | 5                | Conservative treatment\(^{b}\) | Unrelieved+amputation |
| 24             | M   | 53  | TAO      | PCCs             | N     | 36            | 5                | Conservative treatment | Unrelieved |
| 25             | M   | 36  | TAO      | PBMCNs           | N     | 19            | 5                | 2nd transplantation | Ischemia relief |
| 26             | M   | 49  | TAO      | PCCs             | N     | 7             | 5                | 2nd transplantation | Unrelieved |
| 27             | M   | 27  | TAO      | PBMCNs           | N     | 17            | 4                | Conservative treatment\(^{b}\) | Unrelieved |

\(^{a}\) Amputation was performed for this patient because his limb ischemia progressed rapidly and the gangrene was complicated with severe infection.

\(^{b}\) Conservative treatment was performed in these 2 patients for they were in poor general conditions.

Abbreviations: M, male; F, female; TAO, thromboangiitis obliterans; SLE, systemic lupus erythematosus; PBMCNs, peripheral blood mononuclear cells; PCCs, purified CD34+ cells; R, recurrence; N, new lesion.

### Figure 2.
Kaplan-Meier curves showing the probabilities of (A) recurrence-free rate and (B) new lesion-free rate.

\([P = .164]\), without smoking history [OR 0.118, 95% CI 0.012-1.137, \( P = .065 \)]. After the logistic multivariable regression analyses, multiple limbs involved (OR 1.322 95% CI 1.123-1.549, \( P = .036 \)) and ischemia relief period \( \geq 5 \) months (OR 3.367 95% CI 1.112-10.192, \( P = .032 \)) were demonstrated to be independent risk factors for recurrence.
in patients with AICLI who underwent cell transplantation (Table 4).

### Discussion

As one of the largest centers who perform cell therapy for patients with NO-CLI in China, we have performed cell transplantation in more than 200 patients with AICLI over a 12-year period. The long-term efficacy and safety outcomes of cell therapy have been demonstrated by many studies.\(^{3,7-11}\) In light of the fact that patients with AICLI are usually males at a relatively young age and who have a long life expectancy, it is important to measure the durability of cell therapy by observing the recurrence in patients. Recurrence is an event that can only occur after the relief of CLI, and the shortest period between the time of transplantation and recurrence was 8 months in our clinical practice. We decided to enroll 148 patients with AICLI who achieved ischemia relief within 1 year after transplantation and completed a follow-up of at least 12-months in the current study.

In 2018, we reported a study concerning the 5-year outcomes of 27 patients with AICLI who received PCCs transplantation. Three patients with recurrence were observed in this study, and there was a 5-year recurrence rate of 11.11%.\(^{3}\) Likewise, in the current study (with a mean recurrence period of 46.0 ± 30.5 months and a total of 18 patients with recurrence), the 5- and 10-year recurrence-free rates were 88.5% and 71.7%, respectively. These results demonstrated the satisfying durability of cell therapy in treating AICLI. Considering that most recurrence events occurred 24 months posttransplantation (77.8%, 14/18) and that some even occurred after 100 months, and considering the relatively young age of patients with AICLI, a lifelong surveillance of the patients seems to be necessary after cell therapy.

Through univariate analysis and logistic multivariate regression analysis, having multiple limbs involved (Table 4). TAO. Second, multiple ischemic limbs require multiple limbs that need transplantation, although each ischemic limb received adequate CD34\(^+\) dosage (10\(^5-10^6\)/kg) in all patients, the absolute number that each limb received would usually be reduced by half and could even be reduced by three-quarters in patients with all of their limbs affected by ischemia. Finally, for patients with multiple ischemic limbs, especially both of the lower limbs, post-transplantation exercise therapy would be extremely difficult, and the exercise-induced angiogenesis effect would thus be compromised. Additionally, ischemia relief period ≥5 months (OR 3.367 95% CI 1.112-10.192, \(P = .032\)) was also demonstrated to be associated with recurrence. We speculate that a long relief period might indicate a slow response to cell therapy and/or a severe ischemic condition, thus posing a great chance of developing recurrence if lesion progresses.

Although smoke exposure is thought to be closely related to the occurrence and development of TAO,\(^{12-16}\) we did not find smoke cessation to be an independent protective factor, which might be due to the limited number of patients with recurrence and the difficulty in strictly defining smoking cessation (patients with exposure to second-hand smoke in their living or working environment were not classified as smoking cessation). The only female patient who had recurrence in our study, had SLE, which is an incurable systemic autoimmune disease involving multiple systems and organs, and her recurrence was associated with the poor control of her primary disease but was relieved after adequate conservative treatment.

New lesions seemed to be different from recurrence in terms of treatment and prognosis. On the one hand, 3 out of the 18 patients with recurrence achieved ischemia relief via conservative treatment only, and most patients (83.3%, 10/12) who received a second transplantation still achieved ischemia relief (Fig. 3). On the other hand, although the ischemia relief rate after the second transplantation (85.7%, 6/7) was satisfying, patients with new lesions seemed to have just a slight benefit from conservative treatment only. While recurrence seemed to be less severe because it occurred on the basis of prior cell therapy-induced angiogenesis, the new lesions seemed to be associated with poorer prognosis and therefore needed more active intervention. In addition, we found that there was a higher proportion of patients with new lesions who underwent prior PCCs transplantation than prior PBMNCs transplantation (8/69 vs 2/79, \(P = .028\)). Compared

---

### Table 4. Univariate and logistic multivariate analysis of independent risk factors.

| Candidate variable                                      | Univariate analysis OR (95% CI) | P-value | Multivariate analysis OR (95% CI) | P-value |
|--------------------------------------------------------|---------------------------------|---------|----------------------------------|---------|
| Multiple limbs involved                                 | 4.357 (1.162-16.335)            | 0.041   | 1.322 (1.113-25.959)             | 0.036   |
| Ulcer/gangrene with infection                           | 4.500 (1.446-14.003)            | 0.009   | —                                | —       |
| Ischemia relief period ≥5 months                        | 3.254 (1.261-8.397)             | 0.015   | 3.367 (1.112-10.192)             | 0.032   |
| Concurrent debridement                                  | 5.865 (1.672-20.578)            | 0.011   | —                                | —       |
| Post-transplantation smoking condition                  |                                  |         |                                  |         |
| Not quit smoking                                        | —                               | 0.164   | —                                | —       |
| Smoking cessation                                       | 0.791 (0.230-2.714)\(^a\)       | 0.709   | —                                | —       |
| Without smoking history                                 | 0.118 (0.012-1.137)\(^b\)       | 0.065   | —                                | —       |

\(^{a}\)The OR (95% CI) values were calculated compared to patients who did not quit smoking after transplantation.

Abbreviations: OR, odds ratio; CI, confidence interval.
with PCCs, PBMCNs were characterized by a larger volume of autoimplants and a larger number of CD34+ and CD34- cells. Considering that all of the ischemic limbs received CD34+ cells in a certain dosage range (1 x 10^5-1 x 10^6 cells/kg) and the volume of autoimplants seemed unlikely to generate efficacy in the untransplanted limb, the new lesion-proof effect might be related to CD34- cells. CD34- cells are usually thought to be helpful for angiogenesis by playing the role of niche-supporting cells to facilitate cell survival, angiogenic cytokine secretion, and can incorporate capacity and preserve the progenitor status of endothelial progenitor cells (EPCs). Many studies also reported that a certain subpopulation of CD34- cells (CD34-/CD133+) can differentiate into CD34+/CD133+ EPCs and then acquire a mature endothelial phenotype, which is functionally more active than the supposedly more mature CD34+/CD133+ EPC subpopulation. We inferred that the new lesion-proof effect from PBMCNs might result from this important CD34- subpopulation.

There were several limitations in the current study. First, this was a retrospective single-center study, and although a relatively large cohort of patients with AICLI was enrolled, the number of patients with recurrence was still small due to the relatively low rate of recurrence. Second, recurrence is an event that must be associated with some postoperative factors. However, in the current study, only smoking cessation and persistent drug therapy were recorded; in addition, although many patients quit smoking after transplantation, they were still exposed to second-hand smoke, so it was difficult to strictly defined smoking cessation. Finally, only patients whose transplanted limb developed the CLI condition again were enrolled as patients with recurrence while some patients with deteriorated claudication distance was excluded. This might lead to the underestimation of the real number of patients with recurrence.

**Conclusion**

For patients with AICLI who responded to cell transplantation, the durability of this therapy was satisfactory, with 5- and 10-year recurrence-free rates of 88.5% and 71.7%, respectively. Multiple limbs involved at admission and ischemia relief period ≥5 months were demonstrated to be independent risk factors for recurrence after transplantation, suggesting that strict follow-up is needed for such patients. Additionally, it seemed necessary to take active intervention for patients with new lesions for their poor prognosis when they have conservative treatment only.

**Funding**

China National Natural Science Funds (grant no. 81970407, 81900426, 82000452), Grants from Shanghai Excellent Academic Leader (grant no. 19XD1401200), Fudan University “Star of Tomorrow” Famous Doctor Training Project (2019), Shanghai Sailing Program (grant no. 20YF1406600), Shanghai Interventional Therapy Engineering Technology Research Center (grant no. 19DZ2250300), and Clinical Excellent Doctor Training Project (grant no. DGF828008/001/002).

**Conflict of Interest**

The authors indicated no potential conflicts of interest.
Author Contributions
H.L., Y.F.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing. T.P., G.F., Y.L., and X.J.: collection and/or assembly of data, data analysis and interpretation. B.C.: administrative support, provision of study material or patients. Z.W.: collection and/or assembly of data. S.G.: provision of study material or patients. P.L.: administrative support. Z.D., J.Y. and W.F.: conception and design, final approval of manuscript.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

References
1. Norgren L, Hiatt WR, Dormandy JA, et al Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5-S67.
2. Kum S, Tan Y, Schreve M, et al Midterm outcomes from a pilot study of percutaneous deep vein arterialization for the treatment of no-option critical limb ischemia. J Endovasc Ther. 2017;24:619-626.
3. Fang Y, Wei Z, Chen B, et al A five-year study of the efficacy of purified CD34+ cell therapy for angiitis-induced no-option critical limb ischemia. Stem Cells Transl Med. 2018;7:583-590.
4. Kawamoto A, Katayama M, Handa N, et al Intramuscular transplantation of G-CSF-mobilized CD34+ cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009;27:2857-2864.
5. Dong Z, Pan T, Yuan F, et al Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-Month results of a prospective randomised single-blinded non-inferiority trial. EBioMedicine. 2018;35:46-57.
6. Liu H, Pan T, Fang Y, et al Three-year outcomes of peripheral blood mononuclear cells vs purified CD34+ cells in the treatment of angiitis-induced no-option critical limb ischemia and a cost-effectiveness assessment: a randomized single-blinded noninferiority trial. Stem Cells Transl Med. 2021;10:647-659.
7. Jianming G, Lianrui G, Shijun C, et al Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results. Stem Cell Res Ther. 2018;9:43.
8. Gang F, Xiaolang J, Yuan F, et al Autologous peripheral blood-derived stem cells transplantation for treatment of no-option angiitis-induced critical limb ischemia: 10-year management experience. Stem Cell Res Ther. 2020;11:458.
9. Farina MY, Masato K, Yuji T, et al Long-term clinical outcomes of autologous bone marrow mononuclear cell implantation in patients with severe thromboangiitis obliterans. Circ J. 2020;84:650-655.
10. Çağdaş B, Serkan D, Evren O, et al Long-term follow-up of patients with Buerger’s disease after autologous stem cell therapy. Anatol J Cardiol. 2019;21:155-162.
11. Murphy MP, Lawson JH, Rapp BM, et al Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011;53:1565-74.
12. Piazza G, Creager MA. Thromboangiitis obliterans. Circulation. 2010;121(16):1858-61.
13. Vijayakumar A, Tiwari R, Kumar Prabhusswamy V. Thromboangiitis obliterans (Buerger’s disease)-current practices. Int J Inflamm. 2013;2013:156905.
14. Klein-Weigel P, Volz TS, Zange L, Richter J. Buerger’s disease: providing integrated care. J Multidiscip Healthc. 2016;9:511-518.
15. Fazeli B, Dadgar Moghadam M, Niroumand S. How to treat a patient with thromboangiitis obliterans: a systematic review. Ann Vasc Surg. 2018;49:219-228.
16. Fakour F, Fazeli B. Visceral bed involvement in Thromboangiitis obliterans: a systematic review. Vasc Health Risk Manag. 2019;15:317-353.
17. Sahoo S, Klychko E, Thorne T, et al Exosomes from human CD34+ stem cells mediate their proangiogenic paracrine activity. Circ Res. 2011;109:724-728.
18. Kumar AH, Caplice NM. Clinical potential of adult vascular progenitor cells. Arterioscler Thromb Vasc Biol. 2010;30:1080-1087.
19. Mathiyalagan P, Liang Y, Kim D, et al Angiogenic mechanisms of human CD34+ stem cell exosomes in the repair of ischemic hindlimb. Circ Res. 2017;120:1466-76.
20. Lee JH, Lee SH, Yoo SY, Asahara T, Kwon SM. CD34 hybrid cells promote endothelial colony-forming cell bioactivity and therapeutic potential for ischemic diseases. Arterioscler Thromb Vasc Biol. 2013;33(7):1622-1634.
21. Bachelier K, Bergholz C, Friedrich EB. Differentiation potential and functional properties of a CD34-CD133+ subpopulation of endothelial progenitor cells. Mol Med Rep. 2020;21(1):501-507.
22. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34+/CD133+/VEGFR-2+ endothelial cell subpopulation with potent vasoregenerative capacities. Circ Res. 2006;98(3):e20-e25.